Buys | $100,001 | 3 | 60 |
Sells | $967,033 | 2 | 40 |
Brady Stephen R | President and CEO | 1 | $73,850 | 0 | $0 | $73,850 |
Trojanowski Justin | Corporate Controller | 1 | $16,200 | 0 | $0 | $16,200 |
Whiting Samuel | Chief Medical Officer | 1 | $9,951 | 0 | $0 | $9,951 |
Versant Venture Capital VI, L.P. | 10 percent owner | 0 | $0 | 2 | $967,033 | $-967,033 |
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was …
Over the last 12 months, insiders at Tempest Therapeutics, Inc. have bought $100,001 and sold $967,033 worth of Tempest Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Tempest Therapeutics, Inc. have bought $1.71M and sold $967,033 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Brady Stephen R (President and CEO) — $73,850. Trojanowski Justin (Corporate Controller) — $16,200. Whiting Samuel (Chief Medical Officer) — $9,951.
The last purchase of 35,000 shares for transaction amount of $73,850 was made by Brady Stephen R (President and CEO) on 2024‑07‑03.
2024-08-12 | Sale | Versant Venture Capital VI, L.P. | 10 percent owner | 387,999 2.043% | $1.10 | $426,993 | -1.24% | |
2024-08-08 | Sale | Versant Venture Capital VI, L.P. | 10 percent owner | 400,000 1.814% | $1.35 | $540,040 | -29.44% | |
2024-07-03 | Brady Stephen R | President and CEO | 35,000 0.1539% | $2.11 | $73,850 | -53.29% | ||
2024-07-02 | Whiting Samuel | Chief Medical Officer | 4,672 0.0207% | $2.13 | $9,951 | -53.17% | ||
2024-06-28 | Trojanowski Justin | Corporate Controller | 7,500 0.0338% | $2.16 | $16,200 | -53.88% | ||
2022-04-29 | Woiwode Thomas | 2.12M 11.9674% | $2.36 | $5M | -44.60% | |||
2022-01-07 | Dubensky Thomas W. | President | 2,000 0.0288% | $4.78 | $9,560 | -47.73% | ||
2022-01-06 | Whiting Samuel | Chief Medical Officer | 1,700 0.0243% | $4.80 | $8,168 | -48.40% | ||
2016-06-01 | Dipp Michelle | Chief Executive Officer | 425,000 1.3568% | $7.00 | $2.98M | -53.63% | ||
2016-06-01 | ALDRICH RICHARD | director | 425,000 1.3568% | $7.00 | $2.98M | -53.63% | ||
2016-05-18 | Dipp Michelle | Chief Executive Officer | 20,000 0.0671% | $7.86 | $157,200 | -53.14% | ||
2016-05-18 | ALDRICH RICHARD | director | 20,000 0.0671% | $7.86 | $157,200 | -53.14% | ||
2016-05-17 | Dipp Michelle | Chief Executive Officer | 20,000 0.0677% | $7.56 | $151,200 | -50.67% | ||
2016-05-17 | ALDRICH RICHARD | director | 20,000 0.0677% | $7.56 | $151,200 | -50.67% | ||
2016-05-16 | Dipp Michelle | Chief Executive Officer | 20,000 0.0668% | $7.69 | $153,800 | -51.69% | ||
2016-05-13 | Dipp Michelle | Chief Executive Officer | 16,295 0.055% | $7.06 | $115,043 | -46.48% | ||
2016-05-13 | ALDRICH RICHARD | director | 16,295 0.055% | $7.06 | $115,043 | -46.48% | ||
2016-05-12 | Dipp Michelle | Chief Executive Officer | 19,800 0.0679% | $6.84 | $135,352 | -43.52% | ||
2016-05-12 | ALDRICH RICHARD | director | 19,800 0.0679% | $6.84 | $135,352 | -43.52% | ||
2016-05-11 | Dipp Michelle | Chief Executive Officer | 20,000 0.0709% | $7.64 | $152,800 | -47.08% |
Brady Stephen R | President and CEO | 46376 0.1063% | $39,651.48 | 1 | 0 | |
Trojanowski Justin | Corporate Controller | 22168 0.0508% | $18,953.64 | 1 | 0 | |
Whiting Samuel | Chief Medical Officer | 9573 0.0219% | $8,184.92 | 2 | 0 | <0.0001% |
Westphal Christoph H | 3820571 8.7543% | $3.27M | 2 | 0 | ||
Longwood Fund, L.P. | 10 percent owner | 3820571 8.7543% | $3.27M | 2 | 0 |
Tempest Therapeutics, Inc. (TPST) | $22,186,116 | 57 | -43.73% | $37.31M |
$140,938,207 | 36 | 14.75% | $41.76M | |
$23,895,365 | 34 | -37.28% | $37.97M | |
$241,165 | 22 | -16.72% | $40.55M | |
$167,476,357 | 20 | -1.54% | $41.64M |
Increased Positions | 22 | +66.67% | 5M | +171.18% |
Decreased Positions | 12 | -36.36% | 929,854 | -32.7% |
New Positions | 14 | New | 4M | New |
Sold Out Positions | 7 | Sold Out | 803,479 | Sold Out |
Total Postitions | 43 | +30.3% | 7M | +138.48% |
Versant Venture Management, Llc | $2,946.00 | 7.97% | 3.51M | +4M | New | 2024-12-31 |
Blackrock, Inc. | $464.00 | 1.25% | 551,861 | +274 | +0.05% | 2024-12-31 |
Jane Street Group, Llc | $414.00 | 1.12% | 493,094 | +493,094 | New | 2024-12-31 |
Fmr Llc | $363.00 | 0.98% | 431,932 | 0 | 0% | 2024-12-31 |
Geode Capital Management, Llc | $298.00 | 0.81% | 354,276 | +134,209 | +60.99% | 2024-12-31 |
Ubs Group Ag | $164.00 | 0.45% | 195,676 | +187,281 | +2,230.86% | 2024-12-31 |
Millennium Management Llc | $159.00 | 0.43% | 189,506 | +189,506 | New | 2024-12-31 |
Vanguard Group Inc | $148.00 | 0.4% | 176,193 | 0 | 0% | 2024-12-31 |
Xtx Topco Ltd | $135.00 | 0.37% | 160,807 | +136,818 | +570.34% | 2024-12-31 |
Fil Ltd | $109.00 | 0.29% | 129,579 | 0 | 0% | 2024-12-31 |